查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
人類乳突病毒疫苗市場 - 2018-2028年全球行業規模、佔有率、趨勢、機會和預測，按效價、疾病適應症、配銷通路、地區和競爭細分
市場調查報告書
商品編碼
1321043

人類乳突病毒疫苗市場 - 2018-2028年全球行業規模、佔有率、趨勢、機會和預測，按效價、疾病適應症、配銷通路、地區和競爭細分

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Valence, By Disease Indication, By Distribution Channel, By Region, and By Competition
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計全球人類乳突病毒疫苗市場在2024-2028年預測期內將出現令人印象深刻的成長。人類乳突病毒相關疾病的發病率不斷上升，以及政府和私營組織在全球範圍內傳播人類乳突病毒相關意識的舉措的增加，促進市場的成長。人類乳突病毒感染是由人類乳突病毒相關癌症（例如子宮頸癌、陰莖癌和生殖器癌）引起的最常見的性傳播污染。人類乳突病毒疫苗是針對某些類型的人類乳突病毒的免疫接種。它可以預防兩種、四種或九種人類乳突病毒。支持市場成長的因素包括治療性疫苗開發研究的不斷增加、大量臨床試驗、意識的提高和政府投資的增加、減少人類乳突病毒感染的需求不斷成長等。根據 Clinical Trials.gov 的資料，截至2022年 11月，全球約有 394 項與人類乳突病毒疫苗相關的臨床研究處於不同的開發階段。

人類乳突病毒疾病病例不斷增加

肛門、口咽和生殖器等不同器官的人類乳突病毒相關疾病病例激增，顯著增加了對人類乳突病毒疫苗的需求，創造了利潤豐厚的市場成長機會。市場上只有三種類型的疫苗：二價、四價和非價。這三種疫苗都能非常有效地避免 16 型和 18 型病毒的感染，可以治愈 70%的子宮頸癌病例。據美國疾病控制與預防中心 (CDC) 指出，在美國，人類乳突病毒是最常見的性傳播感染。 70%以上的外陰和陰道疾病、60%的陰莖惡性腫瘤、90%的肛門癌和宮頸腫瘤都是由人類乳突病毒引起的。此外，在女性中，子宮頸癌在 9 歲至 30 歲之間非常常見，這刺激了對 HPV 疫苗的需求。例如，根據世界衛生組織的資料，2017年，子宮頸癌導致全球超過25萬女性死亡，其中85%發生在發展中國家。

政府和私人組織越來越多的舉措

在過去的幾年中，各國政府和私人組織已採取多項措施來提高民眾對乳頭瘤病毒的認知，推動人類乳突病毒疫苗市場的成長。這又增加了與人類乳突病毒疫苗相關的研發活動和產品的推出。例如，最近，印度推出了首款針對子宮頸癌的四價人類乳突病毒疫苗（qHPV）。此外，Profectus Biosciences, Inc. 開發 GeneVax prime/VesiculoVax，一種 HPV 治療疫苗。該疫苗對七種人類乳突病毒有效。此外，各組織，特別是聯合國兒童基金會，多年來一直在努力提高疫苗的接受度。泛美衛生組織 (PAHO) 循環基金和聯合國兒童基金會供應部門的影響使得不同國家能夠以較低的價格獲得疫苗。

市場細分

全球人類乳突病毒疫苗市場按效價、疾病適應症、配銷通路和公司細分。根據效價，市場分為二價、四價、非價等。根據疾病適應症，市場分為子宮頸癌、肛門癌、陰道癌、陰莖癌、外陰癌等。根據配銷通路，市場分為醫院和診所、政府和非政府組織、公共和私人聯盟等。就國家而言，由於人類乳突病毒相關疾病的患病率上升以及該國醫療基礎設施的改善，預計美國在預測期內將成為一個利潤豐厚的市場。

市場參與者

Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, and Bharat Biotech International Limited是一些在市場上經營的領先的公司。

可用的客製化

根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。本報告可以使用以下自定義選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第1章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場細分

第2章：研究方法

  • 研究目的
  • 基線方法
  • 主要行業合作夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 資料三角測量和驗證
  • 假設和限制

第3章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第4章：客戶之聲

第5章：臨床試驗分析

  • 進行的臨床試驗
  • 已完成的臨床試驗
  • 終止的臨床試驗
  • 按開發階段分類的管道細分
  • 按狀態分類的管道細分
  • 按研究應用分類的管道細分
  • 按地區分類的管道細分
  • 臨床試驗熱圖

第6章：專利分析

第7章：全球人類乳突病毒疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按效價（二價、四價、非價、其他）
    • 按疾病適應症（子宮頸癌、肛門癌、陰道癌、陰莖癌、外陰癌、其他）
    • 按配銷通路（醫院和診所、政府和非政府組織、公共和私人聯盟、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖
    • 按效價
    • 按疾病適應症
    • 按配銷通路
    • 按地區

第8章：北美人類乳突病毒疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按效價
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第9章：歐洲人類乳突病毒疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按效價
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第10章：亞太地區人類乳突病毒疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按效價
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第11章：南美洲人類乳突病毒疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按效價
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第12章：中東和非洲人類乳突病毒疫苗市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按效價
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非人類乳突病毒疫苗
    • 沙烏地阿拉伯人類乳突病毒疫苗
    • 阿拉伯聯合大公國人類乳突病毒疫苗

第13章：市場動態

  • 促進因素
  • 挑戰

第14章：市場趨勢與發展

  • 最近的發展
  • 併購
  • 產品發布

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（據報導）
  • 最近的發展
  • SWOT分析
    • Serum Institute of India Pvt. Ltd.
    • GlaxoSmithKline Plc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • AstraZeneca Plc
    • Novartis AG
    • Inovio Pharmaceuticals, Inc.
    • Xenetic Biosciences, Inc.
    • Sanofi SA
    • Bharat Biotech International Limited

第16章：戰略建議

簡介目錄
Product Code: 13006

Global human papillomavirus vaccine market is anticipated to observe impressive growth during the forecast period 2024-2028. Growing incidences of Human Papillomavirus Virus-related diseases, along with the rise in initiatives by government and private organizations to spread awareness related to human papillomavirus worldwide, are augmenting the growth of the market. Human papillomavirus infection is the most common sexually transmitted contamination caused by Human Papillomavirus Virus-related cancers such as cervical, penile, and genital cancer. Human papillomavirus vaccines are immunizations that protect from certain types of human papillomavirus. It protects against either two, four, or nine kinds of Human Papillomavirus Virus. The factors supporting the market's growth are the increasing research for the development of therapeutic vaccines, the large number of clinical trials, increasing awareness and government investments, growing need to reduce Human Papillomavirus Virus infections, among others. According to clinical trials.gov, as of November 2022, around 394 clinical studies are in different phases of development related to human papillomavirus vaccines across the globe.

Increasing Cases of Human Papillomavirus Diseases

Upsurge in the cases of Human Papillomavirus related diseases in different organs such as the anal, oropharynx, and genital parts has significantly raised the demand for Human Papillomavirus vaccines, thereby creating lucrative opportunities for market growth. There are just three types of vaccines in the market: bivalent, tetravalent, and nonvalent. All three vaccines are highly effective in avoiding infection with both virus types 16 and 18, which are liable for curing 70% of cervical cancer cases. According to the Centers for Disease Control and Prevention (CDC), in the United States, human papillomavirus is the most common sexually transmitted infection. Over 70% of vulvar and vaginal diseases, 60% of penile malignant growths, and 90% of anal cancer and cervical tumors are caused because of Human Papillomavirus. Moreover, in women, cervical cancer is very common among those age between 9 to 30, which spurs the need for the HPV vaccine. For instance, according to the WHO, in 2017, cervical cancer was liable for over 2,50,000 deaths of women globally, and 85% of these deaths occurred in developing countries.

Increasing Initiatives by Government & Private Organizations

Over the past few years, governments of different nations and private organizations have been taking several steps to create awareness among the population with regard to papillomavirus among the population, thereby driving the growth of the human papillomavirus vaccine market. This has, in turn, increased the research and development activities and products launched related to human papillomavirus vaccine. For instance, recently, India launched the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer. Also, Profectus Biosciences, Inc., is in the process of developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV. The vaccine is believed to be effective against seven Human Papillomavirus kinds. Furthermore, organizations, especially UNICEF, have made efforts to improve vaccine acceptance over the years. The impact of the Pan American Health Organization (PAHO) revolving fund and UNICEF supply division permits vaccinations to be acquired at lower prices for diverse nations.

Market Segmentation

Global human papillomavirus vaccine market is segmented into valence, disease indication, distribution channel, and company. Based on valence, the market is divided into bivalent, quadrivalent, nonvalent, and others. Based on disease indication, the market is categorized into cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, and others. Based on distribution channel, the market is segmented into hospitals & clinics, governmental & non-governmental organizations, public & private alliances, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising prevalence of human papillomavirus-related diseases and better healthcare infrastructure in the country.

Market Players

Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, and Bharat Biotech International Limited are some of the leading companies operating in the market.

Report Scope

In this report, global human papillomavirus vaccine market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Human Papillomavirus Vaccine Market, By Valence:

  • Bivalent
  • Quadrivalent
  • Nonvalent
  • Others

Human Papillomavirus Vaccine Market, By Disease Indication:

  • Cervical Cancer
  • Anal Cancer
  • Vaginal Cancer
  • Penile Cancer
  • Vulvar Cancer
  • Others

Human Papillomavirus Vaccine Market, By Distribution Channel:

  • Hospitals & Clinics
  • Governmental & Non-Governmental Organizations
  • Public & Private Alliances
  • Others

Human Papillomavirus Vaccine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Human Papillomavirus Vaccine Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Patent Analysis

7. Global Human Papillomavirus Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Valence (Bivalent, Quadrivalent, Nonvalent, Others)
    • 7.2.2. By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others)
    • 7.2.3. By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others)
    • 7.2.4. By Region
    • 7.2.5. By Company (2022)
  • 7.3. Market Map
    • 7.3.1. By Valence
    • 7.3.2. By Disease Indication
    • 7.3.3. By Distribution Channel
    • 7.3.4. By Region

8. North America Human Papillomavirus Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Valence
    • 8.2.2. By Disease Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Human Papillomavirus Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Valence
        • 8.3.1.2.2. By Disease Indication
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Human Papillomavirus Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Valence
        • 8.3.2.2.2. By Disease Indication
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Human Papillomavirus Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Valence
        • 8.3.3.2.2. By Disease Indication
        • 8.3.3.2.3. By Distribution Channel

9. Europe Human Papillomavirus Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Valence
    • 9.2.2. By Disease Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Human Papillomavirus Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Valence
        • 9.3.1.2.2. By Disease Indication
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Germany Human Papillomavirus Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Valence
        • 9.3.2.2.2. By Disease Indication
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. United Kingdom Human Papillomavirus Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Valence
        • 9.3.3.2.2. By Disease Indication
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. Italy Human Papillomavirus Vaccine Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Valence
        • 9.3.4.2.2. By Disease Indication
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Spain Human Papillomavirus Vaccine Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Valence
        • 9.3.5.2.2. By Disease Indication
        • 9.3.5.2.3. By Distribution Channel

10. Asia-Pacific Human Papillomavirus Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Valence
    • 10.2.2. By Disease Indication
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Human Papillomavirus Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Valence
        • 10.3.1.2.2. By Disease Indication
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. India Human Papillomavirus Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Valence
        • 10.3.2.2.2. By Disease Indication
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Japan Human Papillomavirus Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Valence
        • 10.3.3.2.2. By Disease Indication
        • 10.3.3.2.3. By Distribution Channel
    • 10.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Valence
        • 10.3.4.2.2. By Disease Indication
        • 10.3.4.2.3. By Distribution Channel
    • 10.3.5. Australia Human Papillomavirus Vaccine Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Valence
        • 10.3.5.2.2. By Disease Indication
        • 10.3.5.2.3. By Distribution Channel

11. South America Human Papillomavirus Vaccine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Valence
    • 11.2.2. By Disease Indication
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Valence
        • 11.3.1.2.2. By Disease Indication
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Argentina Human Papillomavirus Vaccine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Valence
        • 11.3.2.2.2. By Disease Indication
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. Colombia Human Papillomavirus Vaccine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Valence
        • 11.3.3.2.2. By Disease Indication
        • 11.3.3.2.3. By Distribution Channel

12. Middle East and Africa Human Papillomavirus Vaccine Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Valence
    • 12.2.2. By Disease Indication
    • 12.2.3. By Distribution Channel
    • 12.2.4. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Human Papillomavirus Vaccine Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Valence
        • 12.3.1.2.2. By Disease Indication
        • 12.3.1.2.3. By Distribution Channel
    • 12.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Valence
        • 12.3.2.2.2. By Disease Indication
        • 12.3.2.2.3. By Distribution Channel
    • 12.3.3. UAE Human Papillomavirus Vaccine Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Valence
        • 12.3.3.2.2. By Disease Indication
        • 12.3.3.2.3. By Distribution Channel

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

  • 14.1. Recent Developments
  • 14.2. Mergers & Acquisitions
  • 14.3. Product Launches

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (As reported)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Serum Institute of India Pvt. Ltd.
    • 15.6.2. GlaxoSmithKline Plc.
    • 15.6.3. Johnson & Johnson
    • 15.6.4. Merck & Co., Inc.
    • 15.6.5. AstraZeneca Plc
    • 15.6.6. Novartis AG
    • 15.6.7. Inovio Pharmaceuticals, Inc.
    • 15.6.8. Xenetic Biosciences, Inc.
    • 15.6.9. Sanofi SA
    • 15.6.10. Bharat Biotech International Limited

16. Strategic Recommendations